Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538
Characteristics | All (n = 92) | Number of Episodes (%) | OR (95% CI) | p-Value | |
---|---|---|---|---|---|
E. meningoseptica (n = 20) | E. anophelis (n = 72) | ||||
Sex | |||||
Male | 64 (69.6) | 15 (75) | 49 (68.1) | 1.41 (0.46–4.35) | 0.55 |
Female | 28 (30.4) | 5 (25) | 23 (31.9) | 0.71 (0.23–2.19) | 0.55 |
Age | |||||
Range (year) | 3–89 | 18–80 | 3–89 | ||
Median (year) | 61 | 61 | 62.5 | ||
Mean ± standard deviation (year) | 61.1 ± 17 | 56.6 ± 15.6 | 62.4 ± 17.3 | 0.179 | |
Comorbidity | |||||
Diabetes mellitus | 24 (26.1) | 6 (30) | 18 (25) | 1.29 (0.43–3.84) | 0.652 |
Hypertension | 26 (28.3) | 4 (20) | 22 (30.6) | 0.57 (0.17–1.9) | 0.354 |
End-stage renal disease | 5 (5.4) | 1 (5) | 4 (5.6) | 0.9 (0.09–8.49) | 0.999 |
Malignancy | 40 (43.5) | 8 (40) | 32 (44.4) | 0.83 (0.3-2.28) | 0.723 |
Liver cirrhosis | 8 (8.7) | 3 (15) | 5 (6.9) | 2.37 (0.51–10.89) | 0.365 |
Chronic obstructive pulmonary disease | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
Type of infection acquisition | |||||
Community-acquired infection | 10 (10.9) | 20 | 63 (87.5) | 0.197 | |
Healthcare-associated infection | 82 (89.1) | 0 | 9 (12.5) | 0.197 | |
Laboratory data | |||||
White blood cell count (cells/mm3) | 13,281 ± 8740 | 13,353 ± 6687 | 13,261 ± 9271 | 0.967 | |
Hemoglobin (g/dL) | 10.1 ± 2.1 | 9.8 ± 2.4 | 10.1 ± 2.1 | 0.585 | |
Platelet count (×1000 cells/mm3) | 228,570 ± 131,056 | 216,550 ± 157,332 | 231,900 ± 123,846 | 0.69 | |
Serum creatinine (mg/dL) | 1.8 ± 1.7 | 1.6 ± 1.3 | 1.9 ± 1.8 | 0.584 | |
Empirical antimicrobial therapy | |||||
β-lactams | 41 (44.6) | 11 (55) | 30 (41.7) | 1.71 (0.63–4.64) | 0.289 |
β-lactam/lactamase inhibitors | 20 (21.7) | 4 (20) | 16 (22.2) | 0.88 (0.26–2.99) | 0.999 |
Ciprofloxacin | 10 (10.9) | 1 (5) | 9 (12.5) | 0.37 (0.04–3.1) | 0.685 |
Levofloxacin | 24 (26.1) | 1 (5) | 23 (31.9) | 0.11 (0.01–0.89) | 0.015 |
Carbapenems | 17 (18.5) | 4 (20) | 13 (18.1) | 1.14 (0.33–3.96) | 0.999 |
Aminoglycosides | 9 (9.8) | 3 (15) | 6 (8.3) | 1.94 (0.44–8.57) | 0.402 |
Tigecycline | 8 (8.7) | 2 (10) | 6 (8.3) | 1.22 (0.23–6.58) | 0.999 |
Colistin | 6 (6.5) | 1 (5) | 5 (6.9) | 0.71 (0.08–6.41) | 0.999 |
Inappropriate empirical antimicrobial therapy | 74 (80.4) | 20 (100) | 54 (75) | 0.01 | |
Shock | 42 (45.7) | 9 (45) | 33 (45.8) | 0.97 (0.36–2.62) | 0.999 |
Admission to intensive care unit | 44 (47.8) | 9 (45) | 35 (48.6) | 0.87 (0.32–2.34) | 0.775 |
Case fatality | 25 (27.2) | 6 (30) | 19 (26.4) | 1.2 (0.4–3.56) | 0.748 |
Characteristics | All (n = 92) | Number of Episodes (%) | OR (95% CI) | p-Value | |
---|---|---|---|---|---|
E. meningoseptica (n = 20) | E. anophelis (n = 72) | ||||
Sex | |||||
Male | 64 (69.6) | 15 (75) | 49 (68.1) | 1.41 (0.46–4.35) | 0.55 |
Female | 28 (30.4) | 5 (25) | 23 (31.9) | 0.71 (0.23–2.19) | 0.55 |
Age | |||||
Range (year) | 3–89 | 18–80 | 3–89 | ||
Median (year) | 61 | 61 | 62.5 | ||
Mean ± standard deviation (year) | 61.1 ± 17 | 56.6 ± 15.6 | 62.4 ± 17.3 | 0.179 | |
Comorbidity | |||||
Diabetes mellitus | 24 (26.1) | 6 (30) | 18 (25) | 1.29 (0.43–3.84) | 0.652 |
Hypertension | 26 (28.3) | 4 (20) | 22 (30.6) | 0.57 (0.17–1.9) | 0.354 |
End-stage renal disease | 5 (5.4) | 1 (5) | 4 (5.6) | 0.9 (0.09–8.49) | 0.999 |
Malignancy | 40 (43.5) | 8 (40) | 32 (44.4) | 0.83 (0.3-2.28) | 0.723 |
Liver cirrhosis | 8 (8.7) | 3 (15) | 5 (6.9) | 2.37 (0.51–10.89) | 0.365 |
Chronic obstructive pulmonary disease | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
Type of infection acquisition | |||||
Community-acquired infection | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
Healthcare-associated infection | 83 (90.2) | 20 | 63 (87.5) | 0.197 | |
Laboratory data | |||||
White blood cell count (cells/mm3) | 13,281 ± 8740 | 13,353 ± 6687 | 13,261 ± 9271 | 0.967 | |
Hemoglobin (g/dL) | 10.1 ± 2.1 | 9.8 ± 2.4 | 10.1 ± 2.1 | 0.585 | |
Platelet count (×1000 cells/mm3) | 228,570 ± 131,056 | 216,550 ± 157,332 | 231,900 ± 123,846 | 0.69 | |
Serum creatinine (mg/dL) | 1.8 ± 1.7 | 1.6 ± 1.3 | 1.9 ± 1.8 | 0.584 | |
Empirical antimicrobial therapy | |||||
β-lactams | 41 (44.6) | 11 (55) | 30 (41.7) | 1.71 (0.63–4.64) | 0.289 |
β-lactam/lactamase inhibitors | 20 (21.7) | 4 (20) | 16 (22.2) | 0.88 (0.26–2.99) | 0.999 |
Ciprofloxacin | 10 (10.9) | 1 (5) | 9 (12.5) | 0.37 (0.04–3.1) | 0.685 |
Levofloxacin | 24 (26.1) | 1 (5) | 23 (31.9) | 0.11 (0.01–0.89) | 0.015 |
Carbapenems | 17 (18.5) | 4 (20) | 13 (18.1) | 1.14 (0.33–3.96) | 0.999 |
Aminoglycosides | 9 (9.8) | 3 (15) | 6 (8.3) | 1.94 (0.44–8.57) | 0.402 |
Tigecycline | 8 (8.7) | 2 (10) | 6 (8.3) | 1.22 (0.23–6.58) | 0.999 |
Colistin | 6 (6.5) | 1 (5) | 5 (6.9) | 0.71 (0.08–6.41) | 0.999 |
Inappropriate empirical antimicrobial therapy | 74 (80.4) | 20 (100) | 54 (75) | 0.01 | |
Shock | 42 (45.7) | 9 (45) | 33 (45.8) | 0.97 (0.36–2.62) | 0.999 |
Admission to intensive care unit | 44 (47.8) | 9 (45) | 35 (48.6) | 0.87 (0.32–2.34) | 0.775 |
Case fatality | 25 (27.2) | 6 (30) | 19 (26.4) | 1.2 (0.4–3.56) | 0.748 |
Reference
- Lin, J.-N.; Lai, C.-H.; Yang, C.-H.; Huang, Y.-H. Comparison of clinical manifestations, antimicrobial susceptibility patterns, and mutations of fluoroquinolone target genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis isolated in Taiwan. J. Clin. Med. 2018, 7, 538. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lin, J.-N.; Lai, C.-H.; Yang, C.-H.; Huang, Y.-H. Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538. J. Clin. Med. 2019, 8, 546. https://doi.org/10.3390/jcm8040546
Lin J-N, Lai C-H, Yang C-H, Huang Y-H. Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538. Journal of Clinical Medicine. 2019; 8(4):546. https://doi.org/10.3390/jcm8040546
Chicago/Turabian StyleLin, Jiun-Nong, Chung-Hsu Lai, Chih-Hui Yang, and Yi-Han Huang. 2019. "Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538" Journal of Clinical Medicine 8, no. 4: 546. https://doi.org/10.3390/jcm8040546
APA StyleLin, J.-N., Lai, C.-H., Yang, C.-H., & Huang, Y.-H. (2019). Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538. Journal of Clinical Medicine, 8(4), 546. https://doi.org/10.3390/jcm8040546